Search

everythinglearnresearchcommunity

for

Search:↓

CTCL patients can safely continue treatment during COVID-19 with proper safety measures.

CTCF protein is essential for skin and hair follicle development in mice.

The protein CTCF is essential for skin development, maintaining hair follicles, and preventing inflammation.

Hair follicle-derived IL-7 and IL-15 are crucial for maintaining skin-resident memory T cells and could be targeted for treating skin diseases and lymphoma.

Interferon, especially alfa interferon, is an effective treatment for cutaneous T-cell lymphoma with manageable side effects.

The document concludes that treatment for cutaneous T-cell lymphoma should be customized to each patient's disease stage, balancing benefits and side effects, with no cure but many patients living long lives.

COVID-19 vaccination may trigger recurrence of cutaneous T-cell lymphoma in some patients.

VDC-1101 shows potential as a treatment for canine cutaneous T-cell lymphoma.

Interferons are effective for some skin conditions and cancers, but can have side effects and need more research for optimal use.

Some patients with a type of skin lymphoma can experience a rare, non-scarring hair loss that looks like another hair loss condition but has distinct features.

Proper skin toxicity management in chemotherapy is key to continuing treatment and keeping patient quality of life high.

Immunomodulatory therapies are effective for treating cutaneous lymphoma, particularly in early stages.

Hair loss can be caused by stress, infections, drugs, and various diseases, with treatment depending on accurate diagnosis.

A patient with a severe type of hair loss experienced partial hair regrowth after treatment with a specific light therapy and a medication called interferon α2a.

Chemotherapy with carboplatin-paclitaxel causes hair loss in all patients.

The study found no significant link between the symptoms, tissue analysis, and immunofluorescence results in scarring hair loss conditions.

Current treatments for hair loss from chemotherapy are limited, but new methods are being researched.

Chemotherapy can cause skin issues and hair loss, and this guide explains how to manage them.

Blood tests for tumor cells could improve prostate cancer diagnosis and treatment; hair loss severity linked to a gene affecting prostate conditions.

Current methods for grading hair loss from cancer treatment are not accurate enough and need improvement.

Janus kinase inhibitors may help treat cutaneous T-cell lymphoma, but more research is needed.

A new method helps manage skin side effects from hormonal cancer therapy, improving patient care.

Targeting TCR-Vβ2 in cutaneous T cell lymphoma shows promise for safer, more specific treatment.

Folliculotropic mycosis fungoides has unique molecular features and cell interactions that could guide targeted therapy.

Scalp cooling therapy helped over 80% of women keep at least half their hair during chemotherapy.

A 73-year-old woman with Hypopigmented Mycosis Fungoides, a rare skin lymphoma, experienced disease progression despite treatment, emphasizing the need for ongoing monitoring.

A virus protein can activate a pathway that may lead to abnormal hair follicle development.

Hair follicles produce IL-7, which is essential for certain skin lymphoma cells to survive.

Skin problems like acne, dry skin, and nail and hair changes are common in patients taking EGFR inhibitors.

A scalp-cooling system effectively prevents hair loss in breast cancer patients treated with eribulin.